The value of Chief Executive Mike Pearson’s stake in the company had stood at $2.66 billion when Valeant shares peaked at $263.70 on Aug. 5 on the New York Stock Exchange, according to filings. Laval, Quebec-based Valeant on Thursday moved to reassure investors, saying it would address the allegations in detail on a conference call on Monday. Concerns about Valeant are overblown and based on a misunderstanding of how the U.S. drug supply chain works, she said.